Replies to post #213846 on Biotech Values

[Whalatane]

ADRM ...bladerunner ...actual no longer in the stock ...so didn't benefit from the jump today . Forgot why I sold it ...probably got bored with it ...:-)

Believe you were /are in KURA ...congrats on the jump on trial results .
Most of my focus is in FGEN , MYOK , OMER ...either because my wife works in Renal or I know someone connected to the Co..
I've posted about PLSE before ..actually discussed the Co with a Biotech CMO over taco's tonight ( we both have kids on the same soccer team so this was after practice ) ...anyway her view was not to dismiss their science or Robert Duggan .
If nothing else there may be a market treating Canine cancers as many pet owners in the US will often spend over $1,000 on CHOP treatments which usually fail ....but people spend the $ anyway....and I think about 50% of dogs develop some kind of cancer..

A real binary event is coming up with PRTO early next year . This is a stock you should only invest what you can afford to lose. BUT in this final , pivotal P 3 the bar is fairly low ...even 20% longer in fistula patency ( blood flow ) makes this clinically viable as the treatment will only cost about $600 and be done in less then a minute at the time of fistula creation.

Good luck
Kiwi

[lgonber]

ARDM
From amagenmus article on SA, answering your question:
On December 1, 2017, Aradigm completed two Phase 3 trials. One of the two trials in essence failed to meet statistical significance for both the primary endpoint of a median time-to-first-exacerbation versus placebo and the secondary endpoint of a frequency of pulmonary exacerbations over the 48-week treatment period versus placebo. The stock price fell from ~$5.24 to ~$2.17. It traded as low as $0.78 and is now trading at $1.43.
Interestingly, one of Aradigm's main competitors, the much bigger and better-funded Bayer, had a similar treatment failure in one of its two non-cystic fibrosis bronchiectasis trials, as reported on April 5, 2017. In this trial, the 14 day on/off trial succeeded, but the 28 day on/off trial failed.